Change in disability Assessed by: EDSS · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants with serious adverse events · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with serious adverse events compared with interferon beta 1a (moderate certainty).
1 finding from 1 review
Mean Expanded Disability Status Scale score change from baseline · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether alemtuzumab 24 mg changes number of participants experiencing treatment discontinuation caused… compared with interferon beta 1a (very low certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Treament related mortality · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in treament related mortality compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (low certainty).
1 finding from 1 review
Complete response · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in complete response rate compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (moderate certainty).
1 finding from 1 review
Overall survival not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Change in disability Assessed by: EDSS · adults with relapsing–remitting multiple sclerosis
1 finding from 1 review